Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively colle
| Condition(s) | Ulcerative Colitis (Disorder) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed. |
| Who can participate | Inclusion Criteria: * Patients with active ulcerative colitis Exclusion Criteria: * the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease |
| Sex | All |
| Lead sponsor | Showa Inan General Hospital |
| Locations | Komagane, Nagano, Japan |
| Start date | 2025-10-01 |
| NCT ID | NCT07243639 |
| Official listing | https://clinicaltrials.gov/study/NCT07243639 |